Regeneron Pharmaceuticals, Inc. $REGN Shares Newly Bought by VestGen Advisors LLC

VestGen Advisors LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 656 shares of the biopharmaceutical company’s stock, valued at approximately $498,000.

Other large investors have also recently bought and sold shares of the company. Orbimed Advisors LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at about $11,358,000. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $5,682,636,000. Contravisory Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $6,327,000. Oxbow Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $3,342,000. Finally, Deutsche Bank AG acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $323,249,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at approximately $512,550. This trade represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $927.89 on Monday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $591.52 and a 1-year high of $935.35. The firm has a market capitalization of $95.54 billion, a price-to-earnings ratio of 20.49, a PEG ratio of 1.57 and a beta of 0.10. The company has a current ratio of 4.06, a quick ratio of 3.66 and a debt-to-equity ratio of 0.08. The business’s fifty day moving average price is $793.30 and its 200 day moving average price is $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same period last year, the company posted $11.83 earnings per share. The firm’s quarterly revenue was up 36.3% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Analyst Ratings Changes

REGN has been the topic of several recent research reports. Argus upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price target on the stock in a research report on Thursday, October 1st. Piper Sandler raised their price objective on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a research note on Monday, October 19th. Cantor Fitzgerald upped their target price on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a report on Friday, July 31st. HSBC lifted their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Finally, Jefferies Financial Group boosted their price objective on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $850.83.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.